Other highlights from the June 6 JNCI

Aspirin Use, But Not NSAIDS, Associated with Reduced Cancer Risk

In a prospective study, aspirin use was associated with lower risk of cancer incidence and mortality, particularly among former and non-smokers.

The effectiveness of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) in preventing cancer is unclear, and the relationship is complicated further when smoking history is considered.

Aditya Bardia, M.D., of the Mayo Clinic in Rochester, Minn., and colleagues analyzed data from the Iowa Womens Health Study on aspirin and nonaspirin NSAID use, cancer incidence and mortality, and smoking history.

Aspirin use was associated with decreased risk of cancer incidence and mortality, as well as heart disease mortality, compared to people who didnt take aspirin. The association was stronger among former and never smokers than current smokers, although the difference was not statistically significant. Nonaspirin NSAID use was not associated with decreased risk.

Aspirin use could potentially prevent approximately 4.7% of the cancer incidence burden, 3.5% of the cancer mortality burden, and 7.6% of the coronary heart disease mortality burden in the population. Although these percentages may seem small, the impact on public health could be important, the authors write.

Contact: Elizabeth Zimmermann, Mayo Clinic, Department of Public Affairs, zimmermann.elizabeth@mayo.edu, (507) 266-0810

Mutations to Integrin 7 Gene May Promote Cancer Development

A protein called integrin 7 suppresses tumor growth and cell migration, and mutations in the integrin 7 gene are identified in various cancers, including prostate and liver cancer.

Integrins are important adhesive molecules in mammalian cells. Integrin 7 appears to be involved in muscle development and in communication between muscle cells and

Contact: Liz Savage
Journal of the National Cancer Institute

Page: 1 2 3

Related biology news :

1. Other highlights in the Aug. 7 JNCI
2. Other highlights in the July 24 JNCI
3. Other highlights from the July 10 JNCI
4. Other highlights in JNCI, June 26
5. Other highlights in JNCI, June 12
6. Other highlights in the May 16 JNCI
7. Other highlights from the April 18 Journal of the National Cancer Institute
8. Other highlights from the March 21 JNCI
9. Other highlights in the March 7 JNCI
10. Other highlights in the Feb. 21 JNCI
11. Other highlights in the Jan. 17 JNCI

Post Your Comments:

(Date:8/21/2020)... Mass. (PRWEB) , ... August 18, 2020 , ... ... approaches to cell therapy, today announced that the U.S. Food and Drug Administration ... of Sentien’s lead asset, SBI-101, for the treatment of severe COVID-19. Approval of ...
(Date:8/12/2020)... (PRWEB) , ... August 11, 2020 , ... ... subsidiary based in Princeton, NJ, have entered into license agreements with Housey Pharma’s ... development. Both Roche and J&J have annual Research and Development spending in ...
(Date:8/5/2020)... PENSACOLA, Fla. (PRWEB) , ... August 05, 2020 , ... ... to cover two new innovations, CoreText™ and ProText™, making them the first Wharton’s jelly ... a defect using a syringe. The company’s solutions are the first Wharton’s jelly allograft ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... , ... “We are thrilled to deliver this new technology to the industry” ... kind on the market and we were pleased that the IFT jury recognized that.” ... ingredients, creating a natural way to extend the shelf life and improve the safety ...
(Date:7/18/2020)... ... July 17, 2020 , ... dicentra ... life sciences and food industries, is pleased to announce that Charles Galea has ... Business Development. , Charles is an accomplished and results-driven sales executive with over ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... announced today that Massachusetts Institute of Technology (MIT) has expanded the company’s ... allows PathSensors to move into the point-of-care diagnostic market, focusing initially on ...
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, ... the hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. ... of Sentien’s lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor ...
Breaking Biology Technology:
Cached News: